1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer>

About Latona Life Sciences

Latona Life Sciences

Latona Life Sciences, Inc. is a privately-held specialty pharmaceutical company dedicated to the development and commercialization of pharmaceuticals in key therapeutic orphan drug markets.

The company has acquired the rights to the first oral human immunoglobulin, Oralgam™. This product shows potential to serve the Juvenile Idiopathic Arthritis market as well as other immune-mediated diseases.

» Read more...

Juvenile Idiopathic Arthritis

Nurse and ChildJuvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Current estimates of incidence of JIA in the U.S. range from approximately 10 – 100/100,000 children, resulting in current estimates of approximately 100,000 patients under the age of 18.

» Read more...

Immune-Mediated Diseases

Immune-medicated DiseasesThe fundamental concept is that immune-mediated disease results from a selective deficiency in the mucosal immune system of a susceptible individual. The disease process is initiated in the intestinal tract, although the effects of the disease process manifest themselves in tissues and organs far from the intestinal tract. The disease process can be reversed by interfering with this critical step in the expression of immune-mediated disease.

» Read more...

Therapeutic Areas

LaTherapeutic Areastona Life Sciences, Inc. is focused on developing orphan drugs for immune-mediated diseases. Oralgam™ has been granted Orphan Drug Status by the FDA for Juvenile Idiopathic Arthritis (JIA), Dermatomyositis, and autistic enterocolitis.

» Read more...

Investing in Latona Life Sciences, Inc.

Invest in Latona Life SciencesLatona is a privately-held specialty company dedicated to the development and commercialization of pharmaceuticals in key therapeutic orphan drug markets.

» Read more...
Previous
Next

Latona Mission

Latona Life Sciences, Inc. is focused on the development of specialty pharmaceuticals that address the unmet medical needs of individuals with immune-mediated disorders.

Latona Development Focus - Oralgam™

Latona owns the rights to Oralgam, a late Phase II drug used for the treatment of immune-mediated diseases. A novel product, Oralgam has shown efficacy in the treatment of juvenile arthritis in patients who have had limited success with other known pharmaceutical treatments. A platform technology, Oralgam is expected to be clinically tested in other immune-mediated diseases.

Oralgam is a registered trademark of Latona Life Sciences, Inc.